Please ensure Javascript is enabled for purposes of website accessibility

Coronavirus Vaccine Maker Pfizer Posts a Mixed Q4

By Eric Volkman - Feb 2, 2021 at 4:51PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors weren't impressed with the results, despite double-digit percentage increases on both the top and bottom lines.

Pfizer (PFE 1.32%), now famous as the co-developer of the coronavirus vaccine BNT162b2, released its final quarterly results for fiscal 2020 on Tuesday.

These show that the company earned $11.68 billion in revenue, which was 12% higher than the same quarter of 2019. Of that, BNT162b2 -- which received emergency use authorization from the FDA in December -- was responsible for $154 million.

On the bottom line, Pfizer grew its non-GAAP (adjusted) net profit by 15% to nearly $2.37 billion, or $0.42 per share.

Gloved hands holding a vial of medicine.

Image source: Getty Images.

Prognosticators tracking the stock had collectively estimated that the company would book $11.43 billion in revenue, and an adjusted net profit of $0.48 per share.

Pfizer said that Vyndaqel and Vyndamax, treatments for transthyretin amyloidosis that received approval in the European Union (EU) nearly one year ago, were particularly strong sellers. Sales of the related drugs nearly doubled on a year-over-year basis in Q4. As for popular vaccines that aren't BNT162b2, its Prevnar and Prevenar 13 products enjoyed a 10% rise in sales.

In the company's guidance for 2021, it said it anticipates revenue of $59.4 billion to $61.4 billion, compared to a 2020 tally of $41.9 billion. Not surprisingly, BNT162b2 is expected to be a major contributor to this; Pfizer believes the coronavirus vaccine will produce $15 billion in revenue for it.

For 2021, the company upped its adjusted per-share net profit forecast slightly to $3.10 to $3.20. Previously, it was modeling for $3.00 to $3.10. Its 2020 result was $2.22.

On Tuesday, Pfizer stock closed 1.9% lower, in contrast to the 1.5% gain of the S&P 500 index.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
$51.34 (1.32%) $0.67

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.